LiteVax started Phase 1 trial with a novel, adjuvanted, low-dose influenza vaccine (TETRALITE)
Safety, tolerability, and immunogenicity of TETRALITE, a combination of 1/5th of a dose of a licensed influenza vaccine and the novel LiteVax Adjuvant, will be investigated in healthy subjects.